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ess: j.c.virchow@med.uSummary Inhalation therapy delivers therapeutic agents directly into the lungs of
patients with asthma, and is likely to remain the route of delivery of choice for the
foreseeable future. The majority of patients with asthma suffer from mild
intermittent to mild persistent disease for which regular low dose inhaled
corticosteroids and on demand short-acting b2-agonists have been recommended.
These highly effective anti-asthma medications are readily available, and so in the
future improvement in asthma therapy will most likely derive from improvements in
inhaler technology. Dry powder inhalers (DPIs) have many advantages compared to
chlorofluorocarbon pressurised metered dose inhalers. Most notably, with DPIs
patients no longer need to co-ordinate activation of the inhaler with inspiration. The
Novolizers (VIATRIS, Germany) which is one of the latest developments in DPI
technology offers a number of features required to increase the safety and efficacy
of inhaled therapy. It is the first DPI to include an inspiratory trigger threshold, which
helps to prevent sub-optimal dose administration. Repeated activation without
inhalation is mechanically inhibited by an overdose prevention mechanism. In
conclusion, there is good evidence that technically refined DPIs are more likely to
advance inhaled anti-asthmatic therapy than newly developed inhaled drugs. This is
important when inhalation therapy is considered not only for asthma but also for
chronic obstructive pulmonary disease.
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Inhalation therapy is the preferred route of admin-
istration of anti-asthmatic drugs to the airways due
to its rapid, efficient and safe delivery.1 Adverse
events of inhaled medication are markedly reduced
due to the low systemic availability of inhaled
medication compared with systemic doses of
similar anti-asthmatic potency.2 Until recently
most of these drugs were administered as aerosolsed.
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dose inhalers (pMDIs). Since CFCs have been banned
as propellants in order to protect the atmosphere’s
ozone layer,3 hydrofluoroalkane (HFA) propellant
pMDIs have been introduced. Dry powder inhalers
(DPIs) which are propellant-free and accepted for
inhaled asthma therapy have become an increas-
ingly popular alternative to pMDIs as they are
environmentally friendly, easy to use and deliver
more drug to the lungs.4–6 Common to all DPIs is the
fact that desagglomeration of the powdered med-
ication is caused by the inspiratory flow generated
by patients which makes drug delivery inspiratory
flow-dependent. DPIs offer a number of advantages
to conventional CFC-MDIs without necessarily in-
creasing costs. One of their main advantages is that
inhaler activation and inhalation of the aerosol
requires no coordination by the patient. This article
reviews the factors which influence clinicians’
decisions regarding which therapy and which device
to prescribe to patients, to summarise the char-
acteristics of the Novolizers (VIATRIS, Germany) a
recently introduced device with a number of
unique features to deliver medication to the lungs;
and to review clinical trial data with the Novoli-
zers in patients with asthma and chronic obstruc-
tive pulmonary disease (COPD).Which therapy?
The Global INitiative for Asthma (GINA) guidelines
advocates a stepwise approach to both classify
asthma severity and guide treatment. As asthma
severity increases, the dose of inhaled corticoster-
oids (ICSs) is stepped up and other classes of drugs
are added, particularly long-acting b2-agonists
(LABAs). Other agents recommended for addition
to ICS therapy include sustained release theophyl-
line, leukotriene modifiers, long-acting oral b-
agonists and oral corticosteroids, depending on
availability of these drugs and the severity of
asthma. Once control of asthma has been achieved
and maintained for at least three months, a gradual
reduction of the maintenance therapy is recom-
mended to identify the minimum therapy required
to maintain control.1
DPIs can deliver short- and long-acting b-agonists,
corticosteroids, anticholinergics and also combina-
tions of LABAs and ICSs. However, at present it is
unclear whether the use of this combination
(although effective in relieving and preventing
asthmatic airflow obstruction irrespective of its
severity) is indeed necessary and indicated in mild
asthma. Current guidelines recommend their use
only in moderate and severe asthma.1,7 Recentstudies have shown better control of asthma
compared with inhaled corticosteroids alone only
for patients with stage III asthma (FEV1o80% of
predicted).8 Combination treatment has a potential
disadvantage because it does not allow dose
variation of one component if this is needed
according to the actual stage of severity. In contrast
to clinical experience recent animal studies suggest
that regular combination therapy might enhance
features of airway remodelling such as collagen and
fibronectin deposition in the airways.9Which device?
The GINA guidelines recommend DPIs or breath-
activated MDIs for children older than 6 years.1
These guidelines also stipulate that inhalers should
be portable and simple to operate (particularly
important for children), should not require external
power supplies, require minimal co-operation and
coordination and have minimal maintenance re-
quirements.1 Interestingly only the British Thoracic
Society guidelines mention one of the most
important aspects of successful therapy: patients’
preferences and abilities to correctly use the
device should also be considered when deciding
on a specific inhaler.10,11
PMDIs have been used to deliver asthma medica-
tion to the lungs for almost half a century. However,
they have many disadvantages both in terms of
effectiveness and usability. They are inefficient,
typically delivering only about 1/3 of the emitted
dose to the lungs 12,13 and less than half of the
emitted dose to the peripheral airways compared
to DPIs.12,14 They also require good coordination of
inhaler activation and inspiration to ensure correct
inhalation and deposition of drug in the bronchial
tree.15 Misuse of pMDIs has been shown to be the
rule rather than the exception, mainly due to poor
coordination, and this correlates with poorer
asthma control in asthmatic patients treated with
ICS.16 Use of pMDIs without a spacer can lead to the
deposition of a large percentage of the therapeutic
agent in the mouth and pharynx.17 This can be
overcome in part with large volume spacers, which
are cumbersome and bulky and can negatively
affect patients’ compliance. In addition, there are
also significant differences in dose output from
different combinations of pMDIs and spacers.18
Finally, for optimal dose delivery PMDIs require an
optimal inspiratory flow, a full inspiration from
functional residual capacity and a breath hold of at
least 6 s.19 Correct use of MDIs thus requires
intensive training by the physician and regular
technique re-testing may also be necessary.20
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mechanisms nor dose counters. Although HFAs have
reduced the velocity of the aerosol emitted
compared to CFC-aerosols, these pMDIs can still
cause irritation to the back of the throat stopping
patients from inhaling (cold freon effect) which,
occasionally can also cause bronchoconstriction.21
What criteria should be employed when choosing
a device for inhalation therapy? The device itself
should deliver an accurate and reproducible dose
throughout its lifetime to ensure safe drug delivery.
It should be easy and convenient to use, easy to
teach, deliver a range of molecules, have an
accurate dose counter, give patient feedback that
they have used the device correctly, be conveni-
ently carried, robust, visually appealing and CFC-
free. The ability to deliver a range of drugs is
clinically a very important feature since the like-
lihood for errors increases when more than one
inhaler (for different drugs) is used.22 The pulmon-
ary function of the patient and their ability to
correctly use the inhaler device should also be
considered. For example, patients with more
severe airflow obstruction, which might interfere
with a co-ordinated inspiration of a sufficient
inspiratory flow, should preferably be treated with
either a nebuliser, low intrinsic resistance DPI or a
pMDI. Patients who experience difficulty co-ordi-
nating actuation of a pMDI with inspiration might
profit from a DPI where coordination is not
required. Poor coordination using pMDIs is a
common problem,15,16 but can be overcome by
the use of a spacer device. However, patients often
complain that these are bulky and cumbersome to
carry which can affect compliance, especially when
travelling. From a clinical viewpoint it is worth
mentioning that prescribing high quality drugs even
in the most patient-friendly devices can be in-
effective unless patients comply with this treat-
ment. Interestingly, it has been shown that even
patients who experience more than 10 exacerba-
tions per year can have a relatively low compliance
rate.23 Thus any inhaler device which can improve
patient compliance should be regarded as a further
advance in treatment.
A wide variety of DPI systems have been
introduced to the market. Although each of these
devices have unique advantages, unfortunately
they also have many inherent limitations. Most
DPIs currently on the market provide easy and
effective drug delivery. DPIs are all breath-acti-
vated, precluding the need for the patient to co-
ordinate inhaler activation with inhalation. They
do not contain environmentally unfriendly propel-
lants and do not produce unpleasant sensations
during inhalation. The ideal DPI should also providefeedback to the patient and indicate a successful
inhalation (e.g. from optical, acoustic and/or
sensory feedback signals).The Novolizers
Inhaler characteristics
The Novolizers is a multidose, breath-activated,
refillable DPI with several innovative features
offering unique inhalation control and patient
feedback. It is equipped with an inhalation control
system that helps to ensure the deposition of a
particular drug into the bronchial tree. Patients
receive an array of feedback signals indicating
correct and successful inhalation. This is achieved
by: (a) a colour change in the display window which
confirms that powder has been released using
optimal inspiratory flow; (b) a correct inhalation
is confirmed acoustically by a ‘click’ giving the
patient additional feedback on successful actua-
tion; (c) as the carrier particles are lactose, a
sweet taste on the tongue confirms (in combination
with the other feedback features) that drug has
been effectively released; and (d) the Novolizers
also contains a dose counter which resets only after
a correct inhalation, and allows the respective
caregiver to check compliance.
The most important advantage of the Novolizers,
however, is the flow trigger valve system. The
device is activated and releases drug only if a
certain inspiratory flow necessary for drug deposi-
tion in the lower airways is reached. This helps to
ensure sufficient lung deposition as long as an
inspiratory flow in the range of 35–50 L/min or
higher is reached.24 Otherwise, the patient does
not receive any of the feedback mechanisms
mentioned above. This mechanism not only ensures
efficient delivery of the drug to the lower airways
but also overcomes poor patient inhalation techni-
que. The quality of the aerosol delivered by the
Novolizers depends on a helix or cyclone in the
mouthpiece which is needed for desagglomeration
of the aerosol particles and enables maximum
utilisation of the inspiratory flow energy. This
improves flow of drug particles into the bronchial
tree and reduces deposition losses. In addition,
each dose from the Novolizer is almost entirely
emptied from the device ensuring consistency of
dose. Its low-to-medium airflow resistance also
facilitates patients’ inhalation,25 since high resis-
tance DPIs have been shown to release less
medication in response to lower inspiratory
flows 26 and may increase the load on fatigued
respiratory muscles. The device has been shown to
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and neither the emitted dose of the drug nor the
handling of the device is influenced by temperature
or humidity.250 4 8 12
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Figure 1 Effect of 12 weeks treatment with budesonide
(200 mg bd) delivered via the Novolizers or Turbuhalers
on peak expiratory flow (PEF) in patients with mild-to-
moderate asthma. Reprinted with permission from
Chuchalin et al.28Clinical studies
The efficacy, safety and tolerability of the Novoli-
zers have been compared with older inhalation
devices. The effects of salbutamol inhaled from a
Sultanols pMDI or from a Novolizer have been
compared in patients with COPD 27 and the effects
of budesonide administered from a Pulmicort
Turbuhalers or via the Novolizer have been
compared in patients with asthma.27,28
In a randomised, controlled multicentre study,
257 patients with moderate-to-severe COPD includ-
ing patients with asthma were treated with salbu-
tamol (100mg/actuation) using either the
Novolizers or a pMDI.27 Patients attended a two
week run-in phase where they received open-label
treatment with a standard salbutamol pMDI (100mg/
puff). Then a double-dummy single use of salbuta-
mol DPI and MDI was followed by a test of lung
function over 1 h (acute treatment). The study then
continued with an open label, randomised long term
treatment phase with either the Novolizers or
salbutamol MDI for a further 4 weeks. Results
showed that the salbutamol Novolizers and pMDI
were therapeutically equivalent in terms of im-
provement in lung function in these patients with
COPD.27 After 4 weeks of treatment, both groups
showed similar improvements in forced expiratory
volume in 1 s (FEV1), peak expiratory flow (PEF) and
symptom score. The maximum % increase in FEV1
following a single administration of salbutamol was
21.3% in the Novolizers group compared with 19.7%
in the pMDI group. However, the response to
treatment in terms of global assessment of efficacy
was rated as very good/good by more patients in
the Novolizers group (78%) compared to the pMDI
group (69%). Furthermore, of those patients who
had previously used a pMDI (92%), 78% stated that
they would rather use the Novolizers in the future
and 59% expressed a preference for the Novolizers.
Of those patients who had previously used a DPI,
87% favoured the Novolizers to their previous DPI.27
In another randomised, controlled, open-label,
multicentre study, 315 patients with mild-to-
moderate bronchial asthma were treated for 12
weeks with budesonide (200 mg bd) delivered by
either the Novolizers or the Turbuhalers.27,28 The
primary efficacy parameter was FEV1 at the end of
the treatment period. Secondary efficacy variables
included other pulmonary function tests (e.g. PEF),bronchial hyperresponsiveness to histamine, rescue
b2-agonist use, assessment of asthma symptoms
and global assessment of efficacy. The primary
analysis of FEV1 which was the study’s end-
point showed equivalent efficacy between the
Novolizers and the Turbuhalers (Novolizers:
2.71L7X.XL; Turbuhalers: 2.74L7X.XL; Diff:
0.03; 95% CI: 0.19–0.13; Po0:001).27,28 All
other parameters in the pulmonary function tests
as well as asthma symptoms, nocturnal awakenings,
PEF recordings (Fig. 1) and rescue medication use
(Fig. 2) showed no significant or clinically relevant
differences between the two groups. Efficacy was
considered by the investigator to be ‘very good’ or
‘good’ in the majority of patients in both groups
(Novolizers 87%; Turbuhalers 79%). Both groups
had a similarly low incidence of adverse events and
paradoxical bronchospasam. Safety monitoring,
which included vital signs, laboratory, ECG and
ophthalmological findings revealed no evidence
for clinically relevant effects attributable to the
study. Furthermore, the 24 h urinary cortisol con-
centrations were similar in both groups. The
majority of investigators assessed the tolerability
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Figure 3 Effect of treatment with the budesonide
Novolizers on peak expiratory flow (PEF; n ¼ 2191)
and forced expiratory volume in one second (FEV1;
n ¼ 875) of patients with asthma in a post-marketing
surveillance study. Reprinted with permission from
Mo¨ller et al.29
Figure 4 Effect of treatment with the budesonide
Novolizers on asthma symptoms in a post-marketing
surveillance study. Reprinted with permission from
Mo¨ller et al.29
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Figure 2 Effect of 12 weeks treatment with budesonide
(200 mg bd) delivered via the Novolizers or Turbuhalers
on salbutamol usage in patients with mild-to-moderate
asthma. Reprinted with permission from Chuchalin et
al.28
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‘very good’. In summary these results show similar
efficacy, safety and tolerability for the Novolizers
compared to either a pMDI or the Turbuhaler.
Interestingly, in terms of patient preferences the
Novolizers was superior to either MDI or the DPI
used in these studies.
Post marketing surveillance study
The objectives of the post-marketing surveillance
study were to collect data on the efficacy, toler-
ability and acceptance of the Novopulmons 200
Novolizers in patients with asthma.29 The study
comprised 3057 patients from 963 centres in
Germany. The median duration of the monitoring
period was 31 days and the median dose of
budesonide was 400 mg/day. Results showed that
following 4 weeks of treatment with the Novolizers
median PEF increased from 5 to 6.3 L/s and FEV1
increased from 2.25 to 2.7 L (Fig. 3). The severity of
symptoms decreased accordingly during the course
of this surveillance. The median total symptom
score fell from 8 prior to initiation of therapy to 2
at the end of the observation period. The percen-
tage of patients who had symptoms of cough,
wheezing, diurnal dyspnea, nocturnal dyspnea and
dyspnea on physical effort before and after treat-
ment are summarised graphically in Fig. 4.29
Conclusion
The choice of the device for inhalation is a
prerequisite for a successful inhalation therapy.Patients’ pulmonary function and his/her ability to
correctly use a device have to be considered as well
as the efficiency of the device. Requirements for an
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and consistent dose, easy handling by the patient
and feedback mechanisms which indicate success-
ful inhalation. Since the budesonide Novolizers
has been shown to be clinically as effective as
a budesonide Turbuhalers in patients with asthma
and when filled with salbutamol to be as good as a
standard pMDI in patients with COPD, this
new inhalation device with its several feedback
feature offers a patient-friendly alternative
to standard inhalation therapy. This is high-
lighted by the observation that more patients
preferred the Novolizers compared to their
previous MDIs or DPI. In accordance with the GINA
guidelines on asthma therapy the Novolizers
can deliver an ICS (i.e. budesonide) for main-
tenance therapy, as well as a short-acting
b2-agonist (i.e. salbutamol) for as needed treat-
ment of acute episodes of bronchospasam. In
addition the Novolizers can be filled with a
LABA (i.e. formoterol) to treat nocturnal symptoms
or more severe asthma in combination with an
ICS. The Novolizer’ss technical features can
improve efficacy, safety and compliance. In
conclusion, the Novolizers is a DPI which
meets most of the criteria required for an ideal
inhaler device and can deliver a range of
drugs recommended by international manag-
ement guidelines for the treatment of asthma and
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